Biogen reported Phase 2 trial results for diranersen, a tau-targeting therapy for early Alzheimer’s, showing cognitive benefits and reduced tau biomarkers despite missing the primary endpoint. The drug slowed cognitive decline across doses, especially at the lowest dose, and was generally safe. Analysts remain cautiously optimistic about its potential and Biogen plans to continue development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial nephrology drugs to its portfolio, expected to boost revenue by 2027. Biogen’s stock fell nearly 5% following the announcement.
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
